Clinical Trial: A Study to Evaluate the Antiviral Activity and Immune Response of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB)

U.S., May 29 -- ClinicalTrials.gov registry received information related to the study (NCT06993480) titled 'A Study to Evaluate the Antiviral Activity and Immune Response of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB)' on May 16.

Brief Summary: AB-10-8005 is a single-center, open-label Phase II clinical study to evaluate the antiviral activity and immune responses of AHB-137 injection in participants with HBeAg-negative CHB treated with nucleos (t) ide analogues.

Study Start Date: May 19

Study Type: INTERVENTIONAL

Condition: Chronic Hepatitis B

Intervention: DRUG: AHB-137

AHB-137 300 mg will be injected subcutaneously once a week (total 24 weeks).

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Ausper Biopharm...